Clinical Trials | June 12, 2022
Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis
Amarex Clinical Research guides its client to phase II of FDA trials
Amarex Clinical Research guides its client to phase II of FDA trials
Healthcare is timely and personal – and its delivery should be too
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Subscribe To Our Newsletter & Stay Updated
